Theravance Biopharma TBPH
NASDAQ TBPH
$17.03 +0.00 (+0.00%)
At close: Sep 25, 2026 · 4:00 PM EDT

Theravance Biopharma (TBPH) Accumulated Expenses (2014 - 2021)

Updated

Theravance Biopharma's Accumulated Expenses was $252,000 in Q4 2021.

Analysis

Theravance Biopharma (TBPH) Accumulated Expenses (2014 - 2021) Analysis & Trends

  • The Q4 2021 figure marks the highest quarterly Accumulated Expenses since Q2 2014.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Theravance Biopharma 883.70 Mn -543.66 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 252,000.00
Jun 30, 2014 22.34 Mn
API Access

Theravance Biopharma Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=TBPH&period=max&api_key=YOUR_API_KEY